Products
-
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human Dysbindin ELISA Kit (AC2852)
Cat.#: ASET-1441
Specifications
Description Human Dysbindin ELISA Kit allows for the in vitro quantitative determination of human Dysbindin concentrations in serum, plasma, tissue homogenates, and other biological fluids. The kit employs the sandwich enzyme immunoassay technique. Size 96T Sample Type Serum, plasma, tissue homogenates, and other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 46.875 pg/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 78.125-5000 pg/mL Assay Time 4h 30m Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-2220 Human SOCS2 ELISA Kit (AC3631) Quantitative inquiry ASET-1870 Human Myelin Oligodendrocyte Glycoprotein ELISA Kit (AC3281) Quantitative inquiry ASET-1595 Human SPTBN2 ELISA Kit (AC3006) Quantitative inquiry ASET-1812 Human Dynamin 2 ELISA Kit (AC3223) Quantitative inquiry ASET-2428 Human Nurr1 ELISA Kit (AC3839) Quantitative inquiry ASET-1553 Human beta MSH ELISA Kit (AC2964) Quantitative inquiry ASET-2029 Bovine LIF ELISA Kit (AC3440) Quantitative inquiry ASET-1992 Porcine BDNF ELISA Kit (AC3403) Quantitative inquiry ASET-2317 Rat Ghrelin ELISA Kit (AC3728) Quantitative inquiry ASET-2431 Estradiol ELISA Kit (AC3842) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
Quick Links0Inquiry Basket